|1.||Fleckenstein, Lawrence: 8 articles (01/2013 - 06/2007)|
|2.||Borghini-Fuhrer, Isabelle: 6 articles (01/2013 - 04/2010)|
|3.||Duparc, Stephan: 6 articles (01/2013 - 04/2010)|
|4.||Shin, Chang-Sik: 5 articles (01/2013 - 01/2011)|
|5.||Ramharter, Michael: 5 articles (01/2012 - 09/2008)|
|6.||Bélard, Sabine: 4 articles (12/2011 - 09/2008)|
|7.||Kurth, Florian: 4 articles (12/2011 - 09/2008)|
|8.||Poravuth, Yi: 2 articles (04/2012 - 01/2011)|
|9.||Rueangweerayut, Ronnatrai: 2 articles (04/2012 - 01/2011)|
|10.||Valecha, Neena: 2 articles (04/2012 - 01/2011)|
03/01/2000 - "Plasmodium yoelii nigeriensis (MDR)-efficacy of oral pyronaridine against multidrug-resistant malaria in Swiss mice."
06/01/1992 - "A series of in vivo and in vitro experimental studies and the assessment of toxicity revealed pyronaridine to be a promising agent against erythrocytic stage of malaria parasites. "
01/01/1989 - "Hence, an important basis was provided for more rational use and further study of pyronaridine in malaria therapy."
04/01/2011 - "vivax, these data are encouraging evidence for the future implementation of pyronaridine in combination therapy for the fight against malaria."
07/07/2000 - "Pyronaridine: an effective antimalarial against multidrug-resistant malaria."
|2.||Falciparum Malaria (Plasmodium falciparum Malaria)
04/01/1998 - "Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children."
02/01/1996 - "Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand."
01/01/2002 - "The combination of dihydroartemsinin and pyronaridine is an ideal medication scheme for the treatment of falciparum malaria cases with multi-drug resistance."
09/01/1999 - "Short report: effects of pyronaridine on gametocytes in patients with acute uncomplicated falciparum malaria."
02/01/1998 - "Even so, there are new drugs (or new combinations of old drugs) currently under investigation, or in the process of development (at the moment): Pyronaridine, a well-tolerated, synthetic drug that may have utility for multi-resistant falciparum malaria in many parts of the world; however,problems remain over the formulation of this drug (which is a major determinant of its bioavailability) and its eventual cost. "
01/01/1984 - "[Observation on the efficacy of pyronaridine in vivax malaria]."
01/01/2013 - "Pyronaridine-artesunate (PA) is indicated for the treatment of acute uncomplicated Plasmodium falciparum and Plasmodium vivax malaria. "
01/01/2012 - "Clinical pharmacokinetic data for pyronaridine indicates an elimination T1/2 of 13.2 and 9.6 days, respectively, in adults and children with acute uncomplicated falciparum and vivax malaria in artemisinin-combination therapy. "
12/01/2011 - "Pyronaridine-artesunate - currently under evaluation by the European Medicines Agency - may become a preferred choice as first-line therapy in malaria endemic regions based on its low cost, long shelf-life, simplified once-daily dosing regimen, proven efficacy against falciparum and vivax malaria, and the parallel clinical development of a paediatric drug formulation."
01/01/2011 - "Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial."
10/01/1997 - "Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections."
07/07/2000 - "This study shows that pyronaridine is a potentially useful antimalarial drug that could be exploited for the control of multidrug-resistant malaria infection."
01/01/2014 - "Again, there were fewer new infections during the first 28 days in those given artesunate-pyronaridine (PCR-unadjusted treatment failure: RR 0.35, 95% CI 0.17 to 0.73, one trial, 1720 participants, moderate quality evidence), but no differences were detected over the whole 42 days (one trial, 1146 participants, low quality evidence). "
01/01/2014 - "There were fewer new infections during the first 28 days in those given artesunate-pyronaridine (PCR-unadjusted treatment failure: RR 0.60, 95% CI 0.40 to 0.90, two trials, 1720 participants, moderate quality evidence), but no difference was detected over the whole 42 day follow-up (two trials, 1691 participants, moderate quality evidence). "
01/01/1992 - "Extensive field studies involving several thousand cases have shown that pyronaridine has promising therapeutic value in the treatment of malarial infection, including chloroquine-resistant infections. "
|5.||Drug Toxicity (Drug Safety)
06/15/2007 - "This LC-MS method for the determination of pyronaridine in human urine has excellent specifications for sensitivity, reproducibility and accuracy and can reliably quantitate concentrations of pyronaridine in urine as low as 14.3 ng/mL. The method will be used to quantify pyronaridine in human urine for pharmacokinetic and drug safety studies."